Cupid Limited: The Making of a Multibagger – Strong Fundamentals or Market Euphoria?

 

Cupid Limited (NSE: CUPID | BSE: 530843) is an Indian manufacturer and exporter of male and female condoms, personal lubricants and diagnostic kits. Established in 1993, the company has built a global institutional business supplying governments, international agencies and healthcare organizations across 125+ countries.

It is now transitioning from a predominantly export-led healthcare manufacturer into a broader consumer wellness and FMCG company, with products spanning personal care, fragrances, beauty and hygiene.

Source - ET

Financial Performance – Q2 & H1 FY27 (September 2026)

Cupid Limited delivered a strong performance in Q2 FY27, with consolidated revenue from operations rising 122.5% YoY to ₹187.86 crore, compared with ₹84.45 crore in Q2 FY26. Net profit grew 133% to ₹56.22 crore, while EBITDA increased 92.8% to ₹54.77 crore, translating into an EBITDA margin of approximately 29.2%.

For H1 FY27, revenue from operations stood at ₹342.58 crore, registering 137.5% growth over the corresponding period last year. EBITDA increased 155.8% to ₹114.83 crore, while net profit surged 156.5% to ₹100.37 crore. PAT margin improved to 29.3% from 27.1%.

A notable development is the growing contribution of the domestic business, which accounted for 67% of H1 revenue, against 41% in FY26. The Consumer Healthcare & FMCG segment contributed ₹166.88 crore.

Source: ET

Key Observation: While Cupid has delivered impressive revenue growth of 122.5% YoY and net profit growth of 133% in Q2 FY27, the sequential performance warrants attention. Operating Profit declined 8.8% QoQ to ₹54.77 crore despite a 21.4% increase in revenue, resulting in a contraction in EBITDA margin from 38.8% to 29.2%. Additionally, H1 FY27 reported earnings include approximately ₹20 crore in non-operating fair-value gains on investments. Investors should therefore distinguish between underlying operating profitability and investment-related gains while evaluating the sustainability of the company's earnings growth.

Growth triggers: The company is expanding manufacturing capacity at its Palava facility, targeting annual production of 1.25 billion male and 125 million female condoms. Its new V2 Retail partnership covers 425+ stores, with management projecting ₹400 crore revenue over 12 months. It also has an expanding Style Baazar relationship.

Investment perspective: The company offers strong growth visibility, improving profitability and an interesting transition towards the domestic FMCG market. However, its valuation remains extremely demanding, with P/E multiples ranging from 104x to 293x and P/B multiples between 24.8x and 114.9x. The sharp appreciation in the stock price suggests that a significant portion of its anticipated future growth is already priced in. Key takeaway is that the FIIs and DIIs have been increasing their investments over the last one year and promoters pledge has reduced drastically.


Key risk: Execution of ambitious revenue guidance, retail distribution economics and sustainability of earnings growth.

My assessment: A promising high-growth business, but expensive stock. Future returns will depend on delivering the projected growth rather than merely announcing expansion plans.

Note: This is not an Investment recommendation and analysis is purely for Learning. For Investments, please consult your Financial Advisor. Management projections are targets, not assured outcomes. Q2 FY27 earnings also include a substantial fair-value investment gain.


Comments

Popular posts from this blog

The Car That Never Came Home

The FIRE Movement: Freedom or Just Another Rat Race?

💸 The One-Year Delay That Cost Me ₹42 Lakhs: A Personal Lesson in Investing Early